Synbiotics reduce allergen-induced T-helper 2 response and improve peak expiratory flow in allergic asthmatics

Pol, Marianne A. van de; Lutter, René; Smids, Barbara; Weersink, Els J.M.; Zee, Jaring S. van der

doi:10.1111/j.1398-9995.2010.02454.x

Cited by 104 publications

(65 citation statements)

References 40 publications

(40 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although a slightly different ratio of oligosaccharides was used in previous studies (9:1:2), these findings extend earlier observations that a specific prebiotic mixture decreases lower airway hyperreactivity, IgE serum levels, and lung inflammatory cell influx in an ovalbumin-induced murine asthma model (57). Furthermore, it has been reported that administration of scGOS/lcFOS in combination with Bifidobacterium breve M-16V for a period of 4 weeks significantly reduced systemic production of Th2 cytokines after allergen challenge in patients with asthma and house dust mite allergy (53). These studies all underscore the immune-modulating and, more specifically, Th1-supporting effect of these specific oligosaccharide mixtures.…”

Section: Discussionsupporting

confidence: 77%

“…Some nondigestible oligosaccharides are called prebiotics, because they stimulate the growth of commensal bacteria known to be beneficial to the host (38). It has been shown that infant formula including specific nondigestible carbohydrates, like shortchain galactooligosacharides (scGOS) and long-chain fructooligosaccharides (lcFOS), affects the incidence of upper respiratory tract infections and severity of asthma and lowers IgE antibody titers in atopic disease (1,53,54). In addition, in infants receiving scGOS, lcFOS, and pectin-derived oligosaccharides (pAOS), a preventive effect was found for development of atopic dermatitis (17).…”

Section: R Espiratory Syncytial Virus (Rsv) a Pneumovirus In The Familymentioning

confidence: 99%

See 1 more Smart Citation

Specific Dietary Oligosaccharides Increase Th1 Responses in a Mouse Respiratory Syncytial Virus Infection Model

Schijf

Kruijsen

Bastiaans

et al. 2012

J Virol

View full text Add to dashboard Cite

dBreast feeding reduces the risk of developing severe respiratory syncytial virus (RSV) infections in infants. In addition to maternal antibodies, other immune-modulating factors in human milk contribute to this protection. Specific dietary prebiotic oligosaccharides, similar to oligosaccharides present in human milk, were evaluated in a C57BL/6 mouse RSV infection model. During primary RSV infection, increased numbers of RSV-specific CD4 ؉ T cells producing gamma interferon (IFN-␥) were found in the lungs at days 8 to 10 postinfection in mice receiving diet containing short-chain galactooligosacharides, long-chain fructooligosaccharides, and pectin-derived acidic oligosaccharides (termed scGOS/lcFOS/pAOS). In a Th2-skewed formalin-inactivated (FI)-RSV vaccination model, the prebiotic diet reduced RSV-specific Th2 cytokine (interleukin-4 [IL-4], IL-5, and IL-13)-producing CD4؉ T cells in the lung and the magnitude of airway eosinophilia at day 4 and 6 after infection. This was accompanied by a decreased influx of inflammatory dendritic cells (CD11b ؉ /CD11c ؉ ) and increased numbers of IFN-␥-producing CD4 ؉ and CD8؉ T cells at day 8 after viral challenge. These findings suggest that specific dietary oligosaccharides can influence trafficking and/or effector functions of innate immune, CD4؉ , and CD8 ؉ T cell subsets in the lungs of RSV-infected mice. In our models, scGOS/lcFOS/pAOS had no effect on weight but increased viral clearance in FI-RSV-vaccinated mice 8 days after infection. The increased systemic Th1 responses potentiated by scGOS/lcFOS/pAOS might contribute to an accelerated Th1/Th2 shift of the neonatal immune system, which might favor protective immunity against viral infections with a high attack rate in early infancy, such as RSV. R espiratory syncytial virus (RSV), a pneumovirus in the familyParamyxoviridae, infects nearly all children within the first 3 years of life (15). Primary RSV infections can cause severe bronchiolitis and pneumonia, which are associated with significantly increased risk of developing wheeze during childhood that lasts until teenage years (31,45,46). Symptomatic reinfections occur in every age group, but the frequency and severity of symptoms are highest in children below 5 years of age. The mechanism behind the onset of severe RSV infections is still not completely clear. Severe RSV infections that require hospitalization are most frequent in infants 2 to 4 months of age (44). Therefore, it has been proposed that inadequate innate or adaptive responses of the immature immune system contribute to disease severity; in particular, Th2 bias of the immature immune system has been suggested to be an important factor contributing to RSV disease (5, 36).Formation of the intestinal microbiota population, starting directly after birth, is shaped during infancy and is unique for each individual throughout life (23, 37). The intestinal microbiota composition is important for establishment of gut homeostasis and affects local mucosal immunity (20). Although it has been documented tha...

show abstract

Section: Discussionsupporting

confidence: 77%

Section: R Espiratory Syncytial Virus (Rsv) a Pneumovirus In The Familymentioning

confidence: 99%

Specific Dietary Oligosaccharides Increase Th1 Responses in a Mouse Respiratory Syncytial Virus Infection Model

Schijf

Kruijsen

Bastiaans

et al. 2012

J Virol

View full text Add to dashboard Cite

show abstract

“…En una publicación reciente de Van de Pol y col (2010), se demostró que un simbiótico, mezcla de la cepa Bifidobacterium breve M-16V con varios prebióti-cos, reduce significativamente la producción de citocinas Th2 y mejora el pico espiratorio forzado (PEF) después del reto alergénico en adultos asmáticos y alérgicos a los ácaros (42). Otros estudios mostraron que el consumo de diferentes cepas de probióticos mejora los síntomas de la enfermedad alérgica en personas con riesgo de dermatitis atópica (43)(44)(45)(46)(47).…”

Section: Alergiasunclassified

Efectos Clínicos De Los Probióticos: Qué Dice La Evidencia

A¹,

G²,

Poveda³

2012

Rev. chil. nutr.

View full text Add to dashboard Cite

INTRODUCCIÓNA comienzos del siglo XX el científico ElieMetchnikoff (1) postuló su hipótesis acerca de la influencia de la microbiota intestinal sobre el envejecimiento. Según él, los procesos de putrefacción en el intestino permitían la formación de toxinas que contribuían a la degeneración del cuerpo y propuso que el consumo de bacterias ácido lácticas en la leche fermentada podía disminuir los efectos adversos y reducir los procesos dañinos en el organismo (2).En 1930, Minoru Shirota aisló de heces humanas una cepa de Lactobacillus casei que posteriormente cultivó en un medio lácteo para originar una bebida con probió-ticos (2). En 1965, Lilly y Stilwell utilizaron por primera vez el término probiótico para describir aquellas sustancias secretadas por un microorganismo que estimulan el crecimiento de otro, en contraposición al término antibiótico (3). Pero, fue en 1974 cuando Parker utilizó el término como hoy lo conocemos: organismos vivos que al ser ingeridos en cantidades adecuadas confieren un beneficio saludable en el huésped (4). Sin embargo, este concepto continua evolucionando, y actualmente la definición de probióticos es más amplia y estructurada.Los probióticos son microorganismos vivos, principalmente bacterias, no patógenas, utilizados en forma Rev Chil Nutr Vol. 39, Nº1, Marzo 2012 EFECTOS CLÍNICOS DE LOS PROBIÓTICOS:QUÉ DICE LA EVIDENCIA CLINICAL EFECTS OF PROBIOTICS: WHAT DOES THE EVIDENCE SAYSClaudia Manzano A., Diana Estupiñán G., Elpidia Poveda E.Grupo de Investigación Nutrición y Salud, Instituto Alpina. Alpina Productos Alimenticios S.A. Bogotá, Colombia.ABSTRACT The scientific advances related to healthy properties of the probiotics have increased in a significant form. It is evident the positive effects on physiological functions. Considering the relevance in these advances, this review presents a summary of the scientific evidence supporting the principal biological effects of the probiotics in digestive function, systemic immune reply and lipid profile, pathologies relevant in the functional food development.

show abstract

“…87 Also, synbiotics (90% short-chain galacto-oligosaccharides, 10% long-chain fructo-oligosaccharides: Immunofortis and Bifidobacteriu breve M-16V) had no effect on bronchial inflammation and the late asthmatic response but did significantly reduce systemic production of Th2-cytokines after allergen challenge and improved peak expiratory flow for patients with asthma and HDM allergy. 88 The other randomized, double-blind, placebo-controlled, allergy-prevention trial used a combination of LGG, L. rhamnosus LC705, B. breve Bb99 and Propionibacterium freudenreichii ssp. Shermanii prenatally and during the 6 months after birth.…”

Section: Combination Effect Animal Modelmentioning

confidence: 99%

Strategies of mucosal immunotherapy for allergic diseases

Chuang

Chiang

2011

Cell Mol Immunol

View full text Add to dashboard Cite

Incidences of allergic disease have recently increased worldwide. Allergen-specific immunotherapy (SIT) has long been a controversial treatment for allergic diseases. Although beneficial effects on clinically relevant outcomes have been demonstrated in clinical trials by subcutaneous immunotherapy (SCIT), there remains a risk of severe and sometimes fatal anaphylaxis. Mucosal immunotherapy is one advantageous choice because of its non-injection routes of administration and lower side-effect profile. This study reviews recent progress in mucosal immunotherapy for allergic diseases. Administration routes, antigen quality and quantity, and adjuvants used are major considerations in this field. Also, direct uses of unique probiotics, or specific cytokines, have been discussed. Furthermore, some researchers have reported new therapeutic ideas that combine two or more strategies. The most important strategy for development of mucosal therapies for allergic diseases is the improvement of antigen formulation, which includes continuous searching for efficient adjuvants, collecting more information about dominant T-cell epitopes of allergens, and having the proper combination of each. In clinics, when compared to other mucosal routes, sublingual immunotherapy (SLIT) is a preferred choice for therapeutic administration, although local and systemic side effects have been reported. Additionally, not every allergen has the same beneficial effect. Further studies are needed to determine the benefits of mucosal immunotherapy for different allergic diseases after comparison of the different administration routes in children and adults. Data collected from large, well-designed, double-blind, placebo-controlled, and randomized trials, with post-treatment follow-up, can provide robust substantiation of current evidence.

show abstract

Synbiotics reduce allergen-induced T-helper 2 response and improve peak expiratory flow in allergic asthmatics

Abstract: Four-week treatment with synbiotics had no effect on bronchial inflammation and LAR, but did significantly reduce systemic production of Th2-cytokines after allergen challenge and improved PEF.

Cited by 104 publications

References 40 publications

Specific Dietary Oligosaccharides Increase Th1 Responses in a Mouse Respiratory Syncytial Virus Infection Model

Specific Dietary Oligosaccharides Increase Th1 Responses in a Mouse Respiratory Syncytial Virus Infection Model

Efectos Clínicos De Los Probióticos: Qué Dice La Evidencia

Strategies of mucosal immunotherapy for allergic diseases

Contact Info

Product

Resources

About